LIB de­tails Ph3 PC­SK9 in­hibitor da­ta; Eye­n­ovia seeks 's­trate­gic al­ter­na­tives'

Plus, news about In­ozyme and Sen­so­ri­on:

LIB Ther­a­peu­tics touts pos­i­tive Phase 3 cho­les­terol re­sults: The com­pa­ny’s third-gen­er­a­tion PC­SK9 in­hibitor, lero­dal­cibep, achieved a 56% LDL-C re­duc­tion at 52 weeks, ac­cord­ing to da­ta pre­sent­ed Sun­day at the Amer­i­can Col­lege of Car­di­ol­o­gy’s an­nu­al meet­ing. The most com­mon side ef­fects were mild to mod­er­ate in­jec­tion site re­ac­tions. LIB is prepar­ing to file a BLA for lero­dal­cibep this year. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER